01.01.02
Omacor Wins
Approval In Norway
Omacor, produced by Pronova Biocare, Lysaker, Norway, has been approved in Norway for the treatment of post-infarct patients. The formulation is more than 90% omega 3 (84% EPA and DHA) and one capsule per day dosing enhances patient compliance. In clinical trials, side effects were few, transient and mild.
Approval In Norway
Omacor, produced by Pronova Biocare, Lysaker, Norway, has been approved in Norway for the treatment of post-infarct patients. The formulation is more than 90% omega 3 (84% EPA and DHA) and one capsule per day dosing enhances patient compliance. In clinical trials, side effects were few, transient and mild.